Federal Register, Volume 86 Issue 21 (Wednesday, February 3, 2021) 
[Federal Register Volume 86, Number 21 (Wednesday, February 3, 2021)]
[Notices]
[Page 7989]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2021-02234]

========================================================================
Notices
                                                Federal Register
________________________________________________________________________

This section of the FEDERAL REGISTER contains documents other than rules
or proposed rules that are applicable to the public. Notices of hearings
and investigations, committee meetings, agency decisions and rulings,
delegations of authority, filing of petitions and applications and agency
statements of organization and functions are examples of documents
appearing in this section.

========================================================================

Federal Register / Vol. 86, No. 21 / Wednesday, February 3, 2021 /
Notices

[[Page 7989]]

DEPARTMENT OF COMMERCE

Foreign-Trade Zones Board

[B-04-2021]

Foreign-Trade Zone (FTZ) 22--Chicago, Illinois, Notification of
Proposed Production Activity, AbbVie, Inc. (Pharmaceutical Products),
North Chicago and Lake County, Illinois

    AbbVie, Inc. (AbbVie) submitted a notification of proposed
production activity to the FTZ Board for its facilities in North
Chicago and Lake County, Illinois. The notification conforming to the
requirements of the regulations of the FTZ Board (15 CFR 400.22) was
received on January 27, 2021.
    AbbVie already has authority to produce pharmaceutical products
within Subzone 22S. The current request would add a finished product
and a foreign status material to the scope of authority. Pursuant to 15
CFR 400.14(b), additional FTZ authority would be limited to the
specific foreign-status material and specific finished product
described in the submitted notification (as described below) and
subsequently authorized by the FTZ Board.
    Production under FTZ procedures could exempt AbbVie from customs
duty payments on the foreign-status materials/components used in export
production. On its domestic sales, for the foreign-status materials/
components noted below and in the existing scope of authority, AbbVie

would be able to choose the duty rates during customs entry procedures
that applies to IMBRUVICA[supreg] tablets (duty-free). AbbVie would be
able to avoid duty on foreign-status components which become scrap/
waste. Customs duties also could possibly be deferred or reduced on
foreign-status production equipment.
    The material sourced from abroad is Ibrutinib active pharmaceutical
ingredient (duty rate 6.5%). The request indicates that Ibrutinib is
subject to duties under Section 301 of the Trade Act of 1974 (Section
301), depending on the country of origin. The applicable Section 301
decisions require subject merchandise to be admitted to FTZs in
privileged foreign status (19 CFR 146.41).
    Public comment is invited from interested parties. Submissions
shall be addressed to the Board's Executive Secretary and sent to:
ftz@trade.gov. The closing period for their receipt is March 15, 2021.
    A copy of the notification will be available for public inspection
in the ``Reading Room'' section of the Board's website, which is

accessible via www.trade.gov/ftz.
    For further information, contact Christopher Wedderburn at
Chris.Wedderburn@trade.gov.

    Dated: January 28, 2021.
Andrew McGilvray,
Executive Secretary.
[FR Doc. 2021-02234 Filed 2-2-21; 8:45 am]
BILLING CODE 3510-DS-P